Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced the initiation of a Phase II clinical study for its Category 1 innovative drug ABSK021 (pimicotinib) in advanced pancreatic cancer in China, with the first patient now dosed. The multi-center, open-label Phase II study (ABSK021-202) is being conducted across 16 centers in China and aims to evaluate the safety and efficacy of ABSK021 in combination with chemotherapy, as well as in combination with chemotherapy and toripalimab, a drug developed by Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180).
Pimocitinib, an orally administered, highly potent, and selective small-molecule inhibitor of CSF-1R, has received breakthrough therapy designation (BTD) and priority review awards in China, the US, and Europe for the treatment of tendon sheath giant cell tumor (TGCT). The drug is currently undergoing Phase III trials for this indication in both China and the US. Additionally, pimocitinib is the subject of a Phase II clinical study for chronic graft-versus-host disease (cGVHD).- Flcube.com
